Virtus LifeSci Biotech Clinical Trials ETF (BBC) Stock Price & Analysis
Virtus LifeSci Biotech Clinical Trials ETF (BBC) closed at USD 41.22 on Friday, October 23, 2026, down 2.16% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 42.13; the Oct 23, 2026 session ranged USD 40.7–41.22 on volume of 12,680 shares. Market capitalization is —, with a 52-week range of USD 28.73–56.18 (PCX). Source: Nexqual, retrieved October 23, 2026 at 21:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BBC.md
Key facts (BBC)
- Total return with dividends: 1Y +37.1% vs S&P 500 +13.4%; 5Y -4.2% vs S&P 500 +76.9%.
Total return (dividends reinvested) (BBC)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +37.1% | -4.2% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +37.3% | -0.9% |
| Volatility (annualized) | 37.6% | 39.2% |
| Max drawdown | -30.2% (Aug 2026→Oct 2026) | -67.3% (Nov 2021→Mar 2025) |
BBC options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 44.3% | ±10.0% |
| Dec 18, 2026 | 56 | 43.6% | ±13.6% |
| Jan 15, 2027 | 84 | 43.3% | ±16.5% |
| Apr 16, 2027 | 175 | 42.0% | ±23.3% |
30-day implied volatility 44.3% vs 42.1% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 21:24 UTC)
| Price | USD 41.22 |
|---|---|
| Change | ▼ 2.16% (down) |
| Previous Close | USD 42.13 |
| Open | USD 41.94 |
| Day Range | USD 40.7 – 41.22 |
| 52-Week Range | USD 28.73 – 56.18 |
| Volume | 12,680 shares |
| Market Cap | — |
| Exchange | PCX |
Technical Analysis (BBC)
Nexqual's technical model rates BBC "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 21:24 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 35.74 (neutral) |
| vs SMA50 | Below (USD 48.18) |
| MACD | -1.86 (negative) |
Financial Health Score (BBC)
Nexqual rates Virtus LifeSci Biotech Clinical Trials ETF's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 21:24 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBP | Virtus Biotech ETF | USD 102.07 | ▼ 1.82% |
| SBIO | ALPS Medical Breakthroughs ETF | USD 53.38 | ▼ 2.14% |
| FBT | First Trust Amex Biotech Index | USD 269.25 | ▼ 1.26% |
| PBE | Invesco Biotechnology & Genome | USD 98.72 | ▼ 0.67% |
| PTH | Invesco Dorsey Wright Healthcar | USD 58.52 | ▼ 0.67% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 21:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt